Decisions / 7806
final resolution2026-05-07active

Arzneimittel-Richtlinie/Anlage XII: Diflunisal (Hereditäre Transthyretin-Amyloidose mit Polyneuropathie (Stadium 1 oder 2))

Open official decision page ↗

G-BA source · retrieved 2026-08-05

Structured conclusion

Final result by patient group

1 source-verified result

Patient group

Erwachsene mit hereditärer Transthyretin-Amyloidose (hATTR-Amyloidose) mit Polyneuropathie der Stadien 1 oder 2

Added benefit not proven

Comparator
− Vutrisiran

Open official result PDF ↗

Decision orientation

What the G-BA did

4 cited claims

Each claim links to the official G-BA page or an exact PDF page range.

Official metadata

Decision date
2026-05-07
Effective
07.05.2026
Action type
final resolution
Committee
Arzneimittel

Case context

Listed normative targets

directiveArzneimittel-Richtlinie
directive annexAnlage XII: Nutzenbewertung nach § 35a SGB V

A listed target is not treated as a new directive version unless an official version source exists.

Official document package